<DOC>
	<DOCNO>NCT00534430</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor stem cell transplant donor bone marrow transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving mycophenolate mofetil cyclosporine transplant may stop happen . PURPOSE : This phase II trial study side effect best way give busulfan together etoposide total-body irradiation see well work treat patient undergo donor stem cell bone marrow transplant advance hematologic cancer .</brief_summary>
	<brief_title>Busulfan , Etoposide , Total-Body Irradiation Treating Patients Undergoing Donor Stem Cell Bone Marrow Transplant Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine efficacy preparative regimen comprise dose target busulfan , etoposide , fractionate total-body irradiation follow allogeneic hematopoietic stem cell bone marrow transplantation patient advance hematologic malignancy . - To determine efficacy regimen patient acute myeloid leukemia first remission unfavorable cytogenetics . - To evaluate early late toxicity regimen . OUTLINE : - Preparative chemotherapy regimen : Patients receive busulfan IV 2 hour every 6 hour day -14 -8 total 16 dos etoposide IV day -3 . * NOTE : *Patients also receive oral IV dilantin 1-3 time daily day -18 -5 prophylaxis grand mal seizure . - Fractionated total-body irradiation ( FTBI ) : Patients undergo FTBI day -7 -4 total 10 fraction . - Allogeneic transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation bone marrow transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV orally day -1 50 followed taper day 180 absence GVHD . Patients also receive mycophenolate mofetil orally IV 2 hour twice daily day 0-27 , follow taper day 56 . After completion study treatment , patient follow annually 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia ( AML ) Failed remission induction therapy relapse beyond second remission In first remission poor risk cytogenetics ( e.g. , 11q abnormality , 7 , 5 , complex abnormality [ i.e. , &gt; 3 abnormality , 6 ; 9 translocation 3q abnormality del ( 7q ) , del ( 5q ) , complex abnormality ≥ abnormality , 9q , 20q , 21q , 17q , ( 9 ; 21 ) ] ) Acute lymphoblastic leukemia ( ALL ) Failed remission induction therapy relapse beyond second remission Blastic phase chronic myelogenous leukemia Refractory anemia excess blast Refractory anemia excess blast transformation HLA A , B , C , DR identical sibling donor match available No relapse prior bone marrow transplantation PATIENT CHARACTERISTICS : Cardiac ejection fraction ≥ 50 % Serum creatinine ≤ 1.2 time upper limit normal ( ULN ) creatinine clearance &gt; 80 mL/min Bilirubin ≤ 1.5 time ULN AST ALT &lt; 5 time ULN FEV_1 ≥ 50 % predict normal DLCO ≥ 50 % predict normal No psychological medical condition would preclude allogeneic transplantation ( opinion treat physician ) Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior induction reinduction therapy Prior etoposide busulfan allow No prior radiation therapy would exclude totalbody irradiation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>